Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 10/20 | 0.43 |
| ▸ | KDM1B | Q8NB78 | 6/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | APAF1 | O14727 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21999828 | 0.81 | ALDH1A1 (0.34) | KDM1AKDM1BKCNH2ALDH1A1 | |
| SCHEMBL30977427 | 0.77 | ALDH1A1 (0.34) | KDM1AKDM1BKCNH2ALDH1A1 | |
| SCHEMBL31424337 | 0.77 | KDM1A (0.47) | KDM1AKDM1BKCNH2 | |
| SCHEMBL23250453 | 0.77 | KDM1A (0.47) | KDM1AKDM1BKCNH2 | |
| SCHEMBL4568235 | 0.76 | KDM1A (0.41) | KDM1AKDM1BMEN1APAF1ALDH1A1 | |
| SCHEMBL15428005 | 0.75 | MEN1 (0.33) | MEN1APAF1ALDH1A1POLBMAPT | |
| SCHEMBL18840501 | 0.74 | POLB (0.32) | MEN1POLBMAPTKMT2AL3MBTL1 | |
| SCHEMBL2536617 | 0.73 | ALDH1A1 (0.41) | KDM1AKDM1BKCNH2MEN1APAF1 | |
| SCHEMBL24207578 | 0.72 | POLB (0.41) | KDM1AMEN1ALDH1A1POLBMAPT | |
| SCHEMBL21597029 | 0.71 | KDM1A (0.43) | KDM1AKDM1BKCNH2MEN1APAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220106288-A1 | NOVEL SULFONEUREA COMPOUNDS | INFLAZOME LIMITED (IE) | 2022-04-07 | — | — | US | disclosed |
| EP-3837243-A1 | NOVEL SULFONEUREA COMPOUNDS | Inflazome Limited (IE) | 2021-06-23 | — | — | EP | disclosed |
| CN-112888675-A | Novel sulfonylurea compound | 英夫拉索姆有限公司 | 2021-06-01 | — | — | CN | disclosed |
| WO-2020035466-A1 | NOVEL SULFONEUREA COMPOUNDS | INFLAZOME LIMITED (IE) | 2020-02-20 | — | — | WO | disclosed |
| WO-2020035466-A1 | NOVEL SULFONEUREA COMPOUNDS | INFLAZOME LIMITED (IE) | 2020-02-20 | — | — | WO | disclosed |
| EP-2474530-B1 | INDOLE DERIVATIVE AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL (JP) | 2014-09-03 | — | — | EP | disclosed |
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | PTGER1, CYSLTR1, LTB4R | KDM1A 1390/4885KDM1B 1386/4885KCNH2 895/4885 |
| US-20220106288-A1 | NOVEL SULFONEUREA COMPOUNDS | NLRP3, NLRP1, PYCARD | KDM1A 707/4885KDM1B 1900/4885KCNH2 1532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.